MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze GILD →
    • FindStock Picks / Stock Screener
    • Value · GILDIntrinsic Value Calculator
    • Invest · GILDInvestment Case
    • Hold · GILD5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GILD stock logo

GILD

Gilead Sciences, Inc.

$168.08
0.13
 (0.08%)
Exchange:  NASDAQ
Market Cap:  208.476B
Shares Outstanding:  1.244B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Daniel O’Day
Full Time Employees:  17000
Address: 
333 Lakeside Drive
Foster City
CA
94404
US
Website:  https://www.gilead.com
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company’s extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

GILD full analysis

15/02/2026

Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Gilead Sciences, ticker GILD, a heavyweight in the biopharmaceutical space. If you’re looking to understand whether this stock deserves a spot in your portfolio, stick around because we’re covering everything from financials to recent performance, valuation, and more. Let’s get started! Alright, let’s kick things off with a quick overview of what Gilead Sciences is all about. If you’re not familiar, Gilead is a…

Open MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
GIGILD logoGILDGilead Sciences, Inc.208.5B——28.0%
NVNVO logoNVONovo Nordisk A/S184.4B10.912.330.2%
AMAMGN logoAMGNAmgen Inc.251.9B26.819.815.6%
PFPFE logoPFEPfizer Inc.164.7B40.99.58.3%
AZAZN logoAZNAstraZeneca PLC286.1B25.918.013.1%
BMBMY logoBMYBristol-Myers Squibb Company129.7B14.09.914.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/29 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue27,116,00028,754,00029,442,000
Gross Profit20,618,00022,503,00023,208,000
EBITDA10,496,0004,434,00013,580,000
Operating Income7,605,0001,662,00011,701,000
Net Income5,665,000480,0008,510,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets62,125,00058,995,00059,023,000
Total Liabilities39,376,00039,749,00036,405,000
Total Stockholders Equity22,833,00019,330,00022,618,000
Total Debt24,987,00026,711,0000
Cash and Cash Equivalents6,085,0009,991,0000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow8,006,00010,828,00010,019,000
Capital Expenditure-585,000-523,0000
Free Cash Flow7,421,00010,305,00010,019,000
Net Income5,665,000480,0008,510,000
Net Change in Cash673,0003,906,000-2,427,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)38,155,708.203Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)40,710,522.676Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)39,579,835.315Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)22,752,319.962Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)24,543,454.896Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)23,750,755.048Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)16,001,111.962Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)17,409,698.863Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)16,786,302.713Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)7,862,881.485Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)8,389,361.122Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)8,156,356.386Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)13.380Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)13.870Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)12.750Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)10Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
28.727B  ?P/S
 (TTM)
: 
6.73
?Net Income
 (TTM)
: 
480M  ?P/E
 (TTM)
: 
-54.22
?Enterprise Value
 (TTM)
: 
228.27B  ?EV/FCF
 (TTM)
: 
16.57
?Dividend Yield
 (TTM)
: 
1.93%  ?Payout Ratio
 (TTM)
: 
-106.19%
?ROE
 (TTM)
: 
-21.74%  ?ROIC
 (TTM)
: 
27.97%
?Net Debt
 (TTM)
: 
15.754B  ?Debt/Equity
 (TTM)
: 
2.01
?P/B
 (TTM)
: 
16.01  ?Current Ratio
 (TTM)
: 
1.38

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Robust Financial Performance: Gilead Sciences reported strong financial results in the Q4 and full-year 2025 earnings call, with key metrics such as revenue and net income reflecting consistent growth. High gross profit margins (TTM) and positive free cash flow (TTM) underscore operational efficiency and financial stability.
  • Strong Product Portfolio: Revenue from product segments indicates a diversified and resilient portfolio, contributing to sustained revenue streams. The earnings call highlighted successful performance in core therapeutic areas, positioning GILD as a leader in its industry.
  • Healthy Liquidity Position: Balance sheet data shows substantial cash and cash equivalents alongside a favorable current ratio (TTM), indicating the ability to meet short-term obligations and fund strategic initiatives without liquidity constraints.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates GILD intrinsic value between $653.76 – $976.02 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GILD Intrinsic Value

Common questions about GILD valuation

Is Gilead Sciences, Inc. (GILD) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Gilead Sciences, Inc. (GILD) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GILD a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GILD trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GILD’s P/E ratio?

You can see GILD’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GILD?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GILD a good long-term investment?

Whether GILD fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Gilead Sciences, Inc.

  • Gilead Sciences, Inc. intrinsic value calculatorEstimate what the business is worth
  • Gilead Sciences, Inc. 5-year outlookWhat has to go right, and what could go wrong
GILD

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.08
MarketSnap

Trading Metrics:

Open: 168.55   Previous Close: 167.95
Day Low: 166.94   Day High: 169.12
Year Low: 116.88   Year High: 176.58
Price Avg 50: 154.76   Price Avg 200: 141.58
Volume: 3.637M   Average Volume: 6.149M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
12-11-2026 13:20
Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
10-11-2026 14:11
Gilead Sciences, Inc. (GILD) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
10-11-2026 13:16
Gilead Sciences Targets 200 Treatment Centers for Potential Anito-Cel Launch
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
10-11-2026 05:49
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
05-11-2026 05:45
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
02-07-2026 10:00
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze GILD →
    • FindStock Picks / Stock Screener
    • Value · GILDIntrinsic Value Calculator
    • Invest · GILDInvestment Case
    • Hold · GILD5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.